Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

[Bromocriptine-induced pleuropneumopathy]

P A Schmid1, T Suter, R Speich

  • 1Departement für Innere Medizin, Universität Zürich.

Deutsche Medizinische Wochenschrift (1946)
|November 11, 1994
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Terahertz time-domain spectroscopy of materials under high pressure in a diamond anvil cell.

The Review of scientific instruments·2026
Same author

Treatment and outcomes of patients with chronic lung disease and acute myocardial infarction: Insights from the nationwide AMIS plus registry.

European journal of clinical investigation·2024
Same author

Cardiac safety of dual anti-HER2 blockade with pertuzumab plus trastuzumab in early HER2-positive breast cancer in the APHINITY trial.

ESMO open·2023
Same author

Pooled analysis of cardiac safety in patients with cancer treated with pertuzumab.

Annals of oncology : official journal of the European Society for Medical Oncology·2019
Same author

Final efficacy and updated safety results of the randomized phase III BEATRICE trial evaluating adjuvant bevacizumab-containing therapy in triple-negative early breast cancer.

Annals of oncology : official journal of the European Society for Medical Oncology·2016
Same author

Comparison of measurements of the glenopolar angle in 3D CT reconstructions of the scapula and 2D plain radiographic views.

The bone & joint journal·2016
Same journal

Deutsche medizinische Wochenschrift (1946)·2026
Same journal

["Not everything that looks like a tumor..." - Pulmonary tularemia with hilar lymphadenopathy].

Deutsche medizinische Wochenschrift (1946)·2026
Same journal

[Emergency management of sickle cell disease].

Deutsche medizinische Wochenschrift (1946)·2026
Same journal

[Hereditary dehydrated stomatocytosis (= hereditary xerocytosis) - Interesting hummingbird or clinically relevant diagnosis?]

Deutsche medizinische Wochenschrift (1946)·2026
Same journal

[Diagnosis of Congenital Hemolytic Anemias in Adults].

Deutsche medizinische Wochenschrift (1946)·2026
Same journal

[46-year-old female patient with right upper abdominal pain].

Deutsche medizinische Wochenschrift (1946)·2026
See all related articles

This case study suggests bromocriptine, used for Parkinson's disease, may cause serious lung issues. Discontinuing the drug resolved the patient's breathing problems and inflammation.

Area of Science:

  • Neurology
  • Pulmonology
  • Pharmacology

Background:

  • Parkinson's disease is a progressive neurodegenerative disorder.
  • Levodopa and benserazide are common treatments for Parkinson's disease.
  • Bromocriptine is a dopamine agonist sometimes used as an adjunct therapy.

Observation:

  • A 64-year-old male with Parkinson's disease developed exertional dyspnea and weight loss.
  • Chest imaging revealed pleural effusion and interstitial pulmonary changes.
  • Inflammatory markers were elevated, but infection and malignancy were ruled out.

Findings:

  • Pleuropulmonary changes were suspected to be associated with bromocriptine use.
  • Discontinuation of bromocriptine led to significant regression of pleural effusion and normalization of inflammatory markers.

Related Experiment Videos

  • Clinical, biochemical, and radiological tests remained normal after bromocriptine withdrawal.

    • Implications:

    • This case highlights a potential adverse effect of bromocriptine on the pleuropulmonary system.
    • Clinicians should consider bromocriptine-induced lung disease in patients presenting with unexplained respiratory symptoms.
    • Further investigation into the mechanism of bromocriptine-induced pulmonary toxicity is warranted.